4-hydroxy-3,5-diiodo-α-methylphenylacetic acid | 138460-07-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 4-hydroxy-3,5-diiodo-α-methylphenylacetic acid
• 英文别名: 3,5-Diiodo-4-hydroxyphenylpropionic acid；3,5-Diiodo-4-hydroxyphenypropionic acid；2-(4-hydroxy-3,5-diiodophenyl)propanoic acid
• CAS: 138460-07-8
• 化学式: C₉H₈I₂O₃
• 分子量: 417.97
• InChiKey: QTWDFWSFKRKDPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-hydroxy-3,5-diiodo-α-methylphenylacetic acid 在 对甲苯磺酸 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 ethyl 4-(4'-methoxyphenoxy)-3,5-diiodo-α-methylphenylacetate
  参考文献：
  名称：

  .alpha.-Methylated analogs of triiodothyroalkanoic acids: synthesis and biological activity

  摘要：

  Three novel thyroid hormone analogues: alpha-methyl-3,5,3'-triiodothyroacetic acid, alpha-methyl-3,5,3'-triiodothyropropionic acid, and alpha-methyl-3,5,3',5'-tetraiodothyropropionic acid were synthesized. The hepatic thyroid receptor affinity of these analogues was compared to that other available thyroid analogues. The ability of these compounds to increase the activity of two hepatic enzymes and to lower blood cholesterol was compared to that of L-triiodothyronine. alpha-Methyl-3,5,3'-triiodothyroacetic acid was shown to have less nuclear binding affinity, less enzyme inducing ability, but more blood cholesterol lowering ability than triiodothyroacetic acid. alpha-Methyl-3,5,3',5'-tetraiodothyropropionic acid showed less nuclear binding affinity and less enzyme-inducing activity than alpha-methyl-3,5,3'-triiodothyropropionic acid.

  DOI：

  10.1021/jm00081a017
• 作为产物：
  描述：

  2-(4-羟基苯)丙酸 在 碘 、 potassium iodide 作用下， 以88%的产率得到4-hydroxy-3,5-diiodo-α-methylphenylacetic acid
  参考文献：
  名称：

  .alpha.-Methylated analogs of triiodothyroalkanoic acids: synthesis and biological activity

  摘要：

  Three novel thyroid hormone analogues: alpha-methyl-3,5,3'-triiodothyroacetic acid, alpha-methyl-3,5,3'-triiodothyropropionic acid, and alpha-methyl-3,5,3',5'-tetraiodothyropropionic acid were synthesized. The hepatic thyroid receptor affinity of these analogues was compared to that other available thyroid analogues. The ability of these compounds to increase the activity of two hepatic enzymes and to lower blood cholesterol was compared to that of L-triiodothyronine. alpha-Methyl-3,5,3'-triiodothyroacetic acid was shown to have less nuclear binding affinity, less enzyme inducing ability, but more blood cholesterol lowering ability than triiodothyroacetic acid. alpha-Methyl-3,5,3',5'-tetraiodothyropropionic acid showed less nuclear binding affinity and less enzyme-inducing activity than alpha-methyl-3,5,3'-triiodothyropropionic acid.

  DOI：

  10.1021/jm00081a017

文献信息

• Stem Cell Culture Methods
  申请人：Adams David Roger

  公开号：US20120202287A1

  公开（公告）日：2012-08-09

  The invention provides methods for reversibly inhibiting stem cell differentiation wherein a compound of formula (I) is contacted with a stem cell. The invention further provides a method for preparing a culture medium, a culture medium supplement and a composition comprising a compound of formula (I).

  该发明提供了一种可逆抑制干细胞分化的方法，其中将式(I)的化合物与干细胞接触。该发明还提供了一种制备培养基、培养基添加剂和包含式(I)化合物的组合物的方法。
• Radiopaque polymeric stents
  申请人：Kohn B. Joachim

  公开号：US20060034769A1

  公开（公告）日：2006-02-16

  Preferred embodiments of the present invention relate to polymeric medical devices, such as stents. More particularly, the polymeric compositions disclosed herein comprise halogen-containing, tyrosine-derived diphenols, optionally in conjunction with other groups, such as dicarboxylic acids and/or poly(alkylene oxide), such that the medical devices made from these polymeric compositions are bioresorbable and inherently radiopaque, and exhibit physicomechanical properties consistent with the intended uses of such devices.

  本发明的首选实施例涉及聚合物医疗器械，如支架。更具体地说，本文所披露的聚合物组合物包括含卤素的酪氨酸衍生二酚，可选地与其他基团结合，例如二羧酸和/或聚（烷基氧化物），使得由这些聚合物组合物制成的医疗器械具有生物可吸收性和固有的放射性不透明性，并展现出与此类器械预期用途一致的物理力学性能。
• Plasminogen activator inhibitor antagonists
  申请人：Corvas International, Inc.

  公开号：US06638977B1

  公开（公告）日：2003-10-28

  Compounds and pharmaceutical compositions useful as plasminogen activator inhibitor (PAI) antagonists are provided. In particular, methods of antagonizing PAI with substituted and unsubstituted aryl and heteroaryl ethers and thioethers are provided.

  提供了作为纤溶酶原激活物抑制剂（PAI）拮抗剂有用的化合物和药物组合物。具体而言，提供了使用取代和未取代的芳基和杂环基醚和硫醚来拮抗PAI的方法。
• Uses for thyroid hormone compounds
  申请人：KARO BIO AB

  公开号：EP1398024A2

  公开（公告）日：2004-03-17

  A skin treatment composition for topical application comprises: at least one thyroid hormone compound or thyroid hormone-like compound, wherein said thyroid hormone compound or thyroid hormone-like compound is a chemical entity which binds to TRα or TRβ with a dissociation constant, Kd, lower than 1µM, whereinKd = [R] • [L] / [RL], wherein [R] is the concentration of receptor, [L] is the concentration of ligand and [RL] is the concentration of the receptor-ligand complex; at least one ingredient selected from vitamin D, glucocorticoids, retinoids and retinoic acid receptor binding compounds, or analogues thereof; and a pharmacologically acceptable base.

  一种用于局部应用的皮肤治疗组合物包括至少一种甲状腺激素化合物或甲状腺激素样化合物，其中所述甲状腺激素化合物或甲状腺激素样化合物是与 TRα 或 TRβ 结合的化学实体，其解离常数 Kd 低于 1µM，其中 Kd = [R] - [L] / [RL]，其中 [R] 是受体的浓度，[L] 是配体的浓度，[RL] 是受体-配体复合物的浓度；至少一种选自维生素 D、糖皮质激素、维甲酸和维甲酸受体结合化合物或其类似物的成 分；以及药理学上可接受的碱。
• Retinoic acid enhanced human stem cell derived blood brain barrier model
  申请人：Wisconsin Alumni Research Foundation

  公开号：US10590393B2

  公开（公告）日：2020-03-17

  In one embodiment, the present invention is a method of creating a fully-human blood-brain barrier (BBB) model, comprising the steps of (a) obtaining a mixture of neural cells and brain microvascular endothelial cells (BMECs), wherein the neural cells and BMECs that comprise the mixture were produced from the differentiation of human pluripotent stem cells (hPSCs); (b) purifying BMECs from the mixture of neural cells and BMECs of step (a); and (c) co-culturing the purified BMECs with a cell type selected from the group consisting of pericytes, astrocytes and differentiated neural progenitor cells (NPCs), wherein a blood brain barrier model is created.

  在一个实施方案中，本发明是一种创建全人类血脑屏障（BBB）模型的方法，包括以下步骤 (a) 获得神经细胞和脑微血管内皮细胞（BMECs）的混合物，其中构成混合物的神经细胞和 BMECs 是由人多能干细胞（hPSCs）分化产生的；(b) 从步骤(a)的神经细胞和 BMECs 混合物中纯化 BMECs；以及 (c) 将纯化的 BMECs 与选自周细胞、星形胶质细胞和已分化的神经祖细胞（NPCs）的细胞类型共培养，从而创建血脑屏障模型。